|
Session 17
Oral Abstracts
Hepatitis Co-infection
Monday, 4-6 pm
Room: Auditorium |
| 4:00 pm 57 |
HIV Entry and Replication in Stellate Cells Promotes Cellular Activation and Fibrogenesis: Implications for Hepatic Fibrosis in HIV/HCV Co-infection
Ana Tuyama*, F Hong, A Mosoian, P Chen, B Chen, I Fiel, A Schecter, M Klotman, and M Bansal
Mt Sinai Sch of Med, New York, NY, US |
| 4:15 pm 58 |
HIV-related Microbial Translocation, a Mechanism for Liver Disease
A Balagopal1, F Philp1, J Astemborski1, T Block2, A Mehta2, G Kirk1, S Mehta1, A Cox1, S Ray1, and David Thomas*1
1Johns Hopkins Med Inst, Baltimore, MD, US and 2Drexel Inst for Biotech and Virology Res, Doylestown, PA, US |
| 4:30 pm 59 |
Sustained Long-term Antiviral Maintenance with Pegylated Interferon in HCV/HIV-co-infected Patients: Early Viral Response and Effect on Fibrosis in Treated and Control Subjects
Kenneth Sherman*1, J Andersen2, A Butt3, Z Goodman4, T Umbleja2, B Alston6, M Koziel5, M Peters7, M Sulkowski8, R Chung9, and ACTG A5178 Study Team
1Univ of Cincinnati, OH, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Pittsburgh, PA, US; 4Armed Forces Inst of Pathology, Washington, DC, US; 5Beth Israel Deaconess Med Ctr, Boston, MA, US; 6NIAID, NIH, Bethesda, MD, US; 7Univ of California, San Francisco, US; 8Johns Hopkins Univ, Baltimore, MD, US; and 9Massachusetts Gen Hosp, Boston, US |
| 4:45 pm 60 |
Sustained Virological Response to Interferon plus Ribavirin Reduces Liver-related Complications and Mortality in HIV/HCV-co-infected Patients
Juan Berenguer*1, J Alvarez-Pellicer2, J Lopez Aldeguer3, M Von-Wichman4, C Quereda5, J Mallolas6, J Sanz7, C Tural8, J Bellon1, J Gonzalez2, and The GESIDA 3603 Study Group
1Hosp Gregorio Maranon, Madrid, Spain; 2Hosp La Paz, Madrid, Spain; 3Hosp La Fe, Valencia, Spain; 4Hosp Donostia, San Sebastian, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Clin, Barcelona, Spain; 7Hosp Principe de Asturias, Alcala de Henares, Madrid; and 8Hosp Germans Trķas i Pujol, Badalona, Spain |
| 5:00 pm 61LB |
Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with MenRe-infection or Late Relapse?
Rachael Jones*1, D Brown2, M Nelson1, S Bhagani2, M Atkins1, M Danta3, G Dusheiko2, O Pybus4, and D Asboe1
1Chelsea and Westminster NHS Fndn Trust, London, UK; 2Royal Free and Univ Coll Med Sch, London, UK; 3Univ of New South Wales, Sydney, Australia; and 4Oxford Univ, UK |
| 5:15 pm 62 |
3 Interlinked Mechanisms of Inhibition of HIV-1 Reverse Transcriptase by the HBV Drug Entecavir
Egor Tchesnokov*1, A Obikhod2, R Schinazi2, and M Gotte1
1McGill Univ, Montreal, Canada and 2Emory Univ Sch of Med, Atlanta, GA, US |
| 5:30 pm 63 |
The Anti-HIV Activity of Entecavir: Serum HIV RNA Decreases and Selection of the M184V Mutation Occurs in both ART-naļve and -experienced HIV/HBV-co-infected Individuals
Jennifer Audsley*1,2,3, J Sasadeusz1,3, A Mijch1,2, R Baden4, J Caro4,5, H Hunter6, G Matthews7, S Olender8, S Lewin1,2,3, and C Thio9
1Alfred Hosp, Melbourne, Australia; 2Monash Univ, Melbourne, Australia; 3CCREID, Univ of Melbourne, Australia; 4Harvard Med Sch, Boston, MA, US; 5Fenway Community Hlth, Boston, MA, US; 6AID Atlanta, GA, US; 7Natl Ctr in HIV Epi and Clin Res, Sydney, Australia; 8Columbia Univ Med Ctr, New York, NY, US; and 9Johns Hopkins Univ Sch of Med, Baltimore, MD, US |
| 5:45 pm 64 |
MELD is the Best Predictor of Pre-transplant Mortality in HIV-infected Liver Transplant Candidates
Aruna Subramanian*1, M Sulkowski1, B Barin2, D Stablein2, M Curry3, N Nissen4, L Dove5, M Roland6, P Stock7, and M Ragni8
1Johns Hopkins Univ, Baltimore, MD US; 2EMMES Corp, Rockville, MD, US; 3Beth Israel Deaconess Med Ctr, Boston, MA, US; 4Cedars-Sinai Med Ctr, Los Angeles, CA, US; 5Columbia Univ, New York, NY, US; 6California Dept of Publ Hlth, Sacramento, US; 7Univ of California, San Fransisco, US; and 8Univ of Pittsburgh, PA, US |
|
